Frovatriptan is latest molecule in category of triptans, used for migraine therapy. In spite of having great potency and tremendously long half life, this molecule is not used as first line therapy for migraine treatment because of its pharmacokinetic limitations. Preset work is an attempt to surpass the limitations associated with this molecule by delivering it through orotransmucosal route. orotransmucosal route will fasten its onset of action and will increase its bioavailability to atleast 53 %.Also, Present work have the potential to decrease the overall cost of migraine therapy and was designed after considering the complications related to acute migraine attack.